Athenex to Acquire Kuur Therapeutics for ~$185M

 Athenex to Acquire Kuur Therapeutics for ~$185M


  • Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole discretion in either cash or additional Athenex common stock (or a combination of both)
  • The acquisition will expand Athenex’s cell therapy development capability with Kuur’s off-the-shelf engineered CAR-NKT platform and allow the companies to combine CARs and TCRs with the NKT cell platform to target hematological and solid cancers, respectively
  • The platform has the potential to provide synergies with other assets in Athenex’s pipeline

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Athenex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post